Head-to-head comparison
| Property | Sermorelin | Tesamorelin |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Reclassification Pending | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~10-20 minutes | ~26-38 minutes |
| Mol. Weight | 3,357.88 Da | 5,135.89 Da |
| Side Effects | Injection site reactions, Facial flushing, Headache | Injection site reactions (pain, redness), Joint pain, Nausea |
Key differences
- FDA status: Tesamorelin is currently FDA-approved (Egrifta SV for HIV-associated lipodystrophy); sermorelin was previously FDA-approved (Geref for GH deficiency diagnosis) but was withdrawn for commercial reasons.
- Approved indication: Tesamorelin is approved for reducing excess abdominal fat in HIV; sermorelin was approved for diagnostic use, not therapeutic.
- Fat loss evidence: Tesamorelin has Phase III clinical data showing approximately 18% trunk fat reduction; sermorelin does not have comparable fat-specific trial data.
- Potency: Tesamorelin is generally considered more potent for GH stimulation than sermorelin in clinical settings.
- Half-life: Both have relatively short half-lives requiring daily injection. Tesamorelin has modifications that slightly extend its stability compared to native GHRH.
- Cost: Tesamorelin (as a branded FDA-approved product) is significantly more expensive than compounded sermorelin.
- Anti-aging use: Sermorelin is more commonly prescribed in anti-aging clinics due to lower cost and established compounding pharmacy availability; tesamorelin is prescribed for its stronger evidence base.
The verdict
Tesamorelin has the stronger clinical evidence profile with current FDA approval and published fat reduction data. Sermorelin is more widely used in anti-aging and optimization contexts due to lower cost and historical availability through compounding pharmacies. For evidence-based visceral fat reduction, tesamorelin is the supported choice. For general GH optimization at lower cost, sermorelin remains popular. Both stimulate GH through the same GHRH pathway.
Frequently asked questions
Tesamorelin has stronger clinical evidence, including Phase III trial data demonstrating visceral fat reduction. Direct head-to-head comparisons are limited, but tesamorelin is generally considered more potent for GH stimulation. Sermorelin's clinical data is primarily from its diagnostic use, not therapeutic fat reduction.
Sermorelin is significantly less expensive than tesamorelin and has been widely available through compounding pharmacies. Its prior FDA approval history provides prescriber confidence. Tesamorelin's higher cost and specific HIV-lipodystrophy indication make it less commonly prescribed off-label.
Both act on the same GHRH receptor, so combining them would be redundant rather than synergistic. Choosing one GHRH analog and optionally pairing it with a ghrelin-pathway peptide (like ipamorelin) is the standard approach for maximizing GH release.
Tesamorelin has direct clinical trial evidence for reducing visceral (abdominal) fat, with approximately 18% trunk fat reduction demonstrated. Sermorelin lacks comparable fat-specific trial data, though it stimulates the same GH pathway. For evidence-based abdominal fat targeting, tesamorelin is the stronger option.
Yes, both are administered as daily subcutaneous injections due to their relatively short half-lives. This is a significant difference from CJC-1295 with DAC, which can be dosed weekly. Dosing is typically before bedtime to align with natural GH secretion patterns.